Is the vaccine for COVID-19 effective in preventing and treating long COVID?
DOI:
https://doi.org/10.47611/jsrhs.v11i3.3810Keywords:
long COVID, vaccination, COVID-19, symptom, incidenceAbstract
Currently, various types of vaccines have been developed to prevent COVID-19 infection and prevent progression to severe diseases. After COVID-19 infection, a considerable number of patients are complaining of long COVID. However, it has not yet been specifically defined and there is no effective treatment. Therefore, I tried to find out whether vaccination before infection reduced the incidence or worsening symptoms of long COVID from studies reported so far. In addition, I tried to find out whether post-infectious vaccination also relieved symptoms. Long COVID and vaccine-related studies were searched and investigated through Google and the medical search engine. As a result, a total of 12 papers suitable for analysis were summarized. Five studies examined whether vaccination before infection reduced the incidence or symptoms of long COVID, 6 studies examined whether post-infectious vaccination relieved the symptoms of long COVID, and 1 study examined both. In most studies, pre-infection vaccination significantly reduced the incidence of long COVID and relieved long COVID symptoms compared to non-vaccination controls. In addition, post-infection vaccination could significantly reduce the incidence of long COVID. In particular, there was no significant difference between vaccination group and non-vaccination group in the incidence and symptom mitigation of long COVID according to the type of vaccine. In conclusion, vaccination was helpful in preventing and treating long COVID that occur before and even after COVID-19 infection. These findings will be a good guide to recommend vaccinations to unvaccinated people who are still hesitant to vaccinate.
Downloads
References or Bibliography
Aiyegbusi, O. L., Hughes, S. E., Turner, G., Rivera, S. C., McMullan, C., Chandan, J. S., Haroon, S., Price, G., Davies, E. H., Nirantharakumar, K., Sapey, E., Calvert, M. J., & TLC Study Group (2021). Symptoms, complications and management of long COVID: a review. Journal of the Royal Society of Medicine, 114(9), 428–442. https://doi.org/10.1177/01410768211032850
Antonelli, M., Penfold, R. S., Merino, J., Sudre, C. H., Molteni, E., Berry, S., Canas, L. S., Graham, M. S., Klaser, K., Modat, M., Murray, B., Kerfoot, E., Chen, L., Deng, J., Österdahl, M. F., Cheetham, N. J., Drew, D. A., Nguyen, L. H., Pujol, J. C., Hu, C., … Steves, C. J. (2022). Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. The Lancet. Infectious diseases, 22(1), 43–55. https://doi.org/10.1016/S1473-3099(21)00460-6
Arjun, M. C., Singh, A. K., Pal, D., Das, K., Gajjala, A., Venkateshan, M., ... & Subba, S. H. (2022). Prevalence, characteristics, and predictors of Long COVID among diagnosed cases of COVID-19. medRxiv.
Arnold, D. T., Milne, A., Samms, E., Stadon, L., Maskell, N. A., & Hamilton, F. W. (2021). Are vaccines safe in patients with Long COVID? A prospective observational study. MedRxiv.
Ayoubkhani, D., Bermingham, C., Pouwels, K. B., Glickman, M., Nafilyan, V., Zaccardi, F., ... & Walker, A. S. (2021). Changes in the trajectory of Long Covid symptoms following COVID-19 vaccination: community-based cohort study. medRxiv.
Barda, N., Dagan, N., Cohen, C., Hernán, M. A., Lipsitch, M., Kohane, I. S., Reis, B. Y., & Balicer, R. D. (2021). Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet (London, England), 398(10316), 2093–2100. https://doi.org/10.1016/S0140-6736(21)02249-2
Callaway E. (2021). Fast-spreading COVID variant can elude immune responses. Nature, 589(7843), 500–501. https://doi.org/10.1038/d41586-021-00121-z
Chen, M., Yuan, Y., Zhou, Y., Deng, Z., Zhao, J., Feng, F., Zou, H., & Sun, C. (2021). Safety of SARS-CoV-2 vaccines: a systematic review and meta-analysis of randomized controlled trials. Infectious diseases of poverty, 10(1), 94. https://doi.org/10.1186/s40249-021-00878-5
Corman, V. M., Muth, D., Niemeyer, D., & Drosten, C. (2018). Hosts and Sources of Endemic Human Coronaviruses. Advances in virus research, 100, 163–188. https://doi.org/10.1016/bs.aivir.2018.01.001
COVID-19 rapid guideline: managing the long-term effects of COVID-19. (2020). National Institute for Health and Care Excellence (NICE).
Cunningham, J. W., Vaduganathan, M., Claggett, B. L., Jering, K. S., Bhatt, A. S., Rosenthal, N., & Solomon, S. D. (2020). Clinical Outcomes in Young US Adults Hospitalized With COVID-19. JAMA internal medicine, 181(3), 379–381. Advance online publication. https://doi.org/10.1001/jamainternmed.2020.5313
Gaber, T. A. K., Ashish, A., Unsworth, A., & Martindale, J. (2021). Are mRNA covid 19 vaccines safe in long covid patients? A health care workers perspective. British Journal of Medical Practitioners, 14(1), NA-NA.
Klugar, M., Riad, A., Mohanan, L., & Pokorná, A. (2021). COVID-19 Vaccine Booster Hesitancy (VBH) of Healthcare Workers in Czechia: National Cross-Sectional Study. Vaccines, 9(12), 1437. https://doi.org/10.3390/vaccines9121437
Kuodi, P., Gorelik, Y., Zayyad, H., Wertheim, O., Wiegler, K. B., Abu Jabal, K., Dror, A. A., Nazzal, S., Glikman, D., & Edelstein, M. (2022). Association between BNT162b2 vaccination and reported incidence of post-COVID-19 symptoms: cross-sectional study 2020-21, Israel. NPJ vaccines, 7(1), 101. https://doi.org/10.1038/s41541-022-00526-5
Larsen, J. R., Martin, M. R., Martin, J. D., Kuhn, P., & Hicks, J. B. (2020). Modeling the Onset of Symptoms of COVID-19. Frontiers in public health, 8, 473. https://doi.org/10.3389/fpubh.2020.00473
Ling, Y., Zhong, J., & Luo, J. (2021). Safety and effectiveness of SARS-CoV-2 vaccines: A systematic review and meta-analysis. Journal of medical virology, 93(12), 6486–6495. https://doi.org/10.1002/jmv.27203
Massey, D., Berrent, D., Akrami, A., Assaf, G., Davis, H., Harris, K., ... & Iwasaki, A. (2021). Change in symptoms and immune response in people with post-acute sequelae of SARS-Cov-2 infection (PASC) after SARS-Cov-2 vaccination. MedRxiv.
Proal, A. D., & VanElzakker, M. B. (2021). Long COVID or Post-acute Sequelae of COVID-19 (PASC): An Overview of Biological Factors That May Contribute to Persistent Symptoms. Frontiers in microbiology, 12, 698169. https://doi.org/10.3389/fmicb.2021.698169
Raveendran, A. V., Jayadevan, R., & Sashidharan, S. (2021). Long COVID: An overview. Diabetes & metabolic syndrome, 15(3), 869–875. https://doi.org/10.1016/j.dsx.2021.04.007
Riad, A., Hocková, B., Kantorová, L., Slávik, R., Spurná, L., Stebel, A., Havriľak, M., & Klugar, M. (2021). Side Effects of mRNA-Based COVID-19 Vaccine: Nationwide Phase IV Study among Healthcare Workers in Slovakia. Pharmaceuticals (Basel, Switzerland), 14(9), 873. https://doi.org/10.3390/ph14090873
Salamanna, F., Veronesi, F., Martini, L., Landini, M. P., & Fini, M. (2021). Post-COVID-19 Syndrome: The Persistent Symptoms at the Post-viral Stage of the Disease. A Systematic Review of the Current Data. Frontiers in medicine, 8, 653516. https://doi.org/10.3389/fmed.2021.653516
Scherlinger, M., Pijnenburg, L., Chatelus, E., Arnaud, L., Gottenberg, J. E., Sibilia, J., & Felten, R. (2021). Effect of SARS-CoV-2 Vaccination on Symptoms from Post-Acute Sequelae of COVID-19: Results from the Nationwide VAXILONG Study. Vaccines, 10(1), 46. https://doi.org/10.3390/vaccines10010046
Simon, M. A., Luginbuhl, R. D., & Parker, R. (2021). Reduced Incidence of Long-COVID Symptoms Related to Administration of COVID-19 Vaccines Both Before COVID-19 Diagnosis and Up to 12 Weeks After. medRxiv.
Strain, W. D., Sherwood, O., Banerjee, A., Van der Togt, V., Hishmeh, L., & Rossman, J. (2022). The Impact of COVID Vaccination on Symptoms of Long COVID: An International Survey of People with Lived Experience of Long COVID. Vaccines, 10(5), 652. https://doi.org/10.3390/vaccines10050652
Taquet, M., Dercon, Q., & Harrison, P. J. (2022). Six-month sequelae of post-vaccination SARS-CoV-2 infection: A retrospective cohort study of 10,024 breakthrough infections. Brain, behavior, and immunity, 103, 154–162. https://doi.org/10.1016/j.bbi.2022.04.013
Wanga, V., Chevinsky, J. R., Dimitrov, L. V., Gerdes, M. E., Whitfield, G. P., Bonacci, R. A., Nji, M., Hernandez-Romieu, A. C., Rogers-Brown, J. S., McLeod, T., Rushmore, J., Lutfy, C., Bushman, D., Koumans, E., Saydah, S., Goodman, A. B., Coleman King, S. M., Jackson, B. R., & Cope, J. R. (2021). Long-Term Symptoms Among Adults Tested for SARS-CoV-2 - United States, January 2020-April 2021. MMWR. Morbidity and mortality weekly report, 70(36), 1235–1241. https://doi.org/10.15585/mmwr.mm7036a1
Wisnivesky, J. P., Govindarajulu, U., Bagiella, E., Goswami, R., Kale, M., Campbell, K. N., Meliambro, K., Chen, Z., Aberg, J. A., & Lin, J. J. (2022). Association of Vaccination with the Persistence of Post-COVID Symptoms. Journal of general internal medicine, 37(7), 1748–1753. https://doi.org/10.1007/s11606-022-07465-w
Soriano, J. B., Murthy, S., Marshall, J. C., Relan, P., Diaz, J. V., & WHO Clinical Case Definition Working Group on Post-COVID-19 Condition (2022). A clinical case definition of post-COVID-19 condition by a Delphi consensus. The Lancet. Infectious diseases, 22(4), e102–e107. https://doi.org/10.1016/S1473-3099(21)00703-9
Wu, Z., & McGoogan, J. M. (2020). Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA, 323(13), 1239–1242. https://doi.org/10.1001/jama.2020.2648
Published
How to Cite
Issue
Section
Copyright (c) 2022 Stephen Kim, Hyun Kang
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright holder(s) granted JSR a perpetual, non-exclusive license to distriute & display this article.
